REPORT/RECOMMENDATION TO THE BOARD OF SUPERVISORS
OF SAN BERNARDINO COUNTY
AND RECORD OF ACTION
September 24, 2024
FROM
ANDREW GOLDFRACH, ARMC Chief Executive Officer, Arrowhead Regional Medical Center
SUBJECT
Title
Sales Pricing Agreement with Endologix, LLC for the Provision of Percutaneous Arterial Bypass Graft and Endovascular Products
End
RECOMMENDATION(S)
Recommendation
Approve Sales Pricing Agreement, including non-standard terms, with Endologix, LLC for the provision of percutaneous arterial bypass graft and endovascular products, in an amount not to exceed $480,000, for the period of September 24, 2024 through May 31, 2026.
(Presenter: Andrew Goldfrach, ARMC Chief Executive Officer, 580-6150)
Body
COUNTY AND CHIEF EXECUTIVE OFFICER GOALS & OBJECTIVES
Provide for the Safety, Health and Social Service Needs of County Residents.
FINANCIAL IMPACT
Approval of this item will not result in the use of Discretionary General Funding (Net County Cost). The cost of $480,000 is funded by the State Medi-Cal, Federal Medicare, private insurances, and other departmental revenue. Funding sources may change in the future pending any legislative activity related to the repeal and/or replacement of the Affordable Care Act. Adequate appropriation and revenue have been included in the Arrowhead Regional Medical Center (ARMC) 2024-25 budget and will be included in the 2025-26 recommended budget.
BACKGROUND INFORMATION
The Agreement with Endologix, LLC (Endologix) will allow ARMC to purchase the Detour System and the ALTO Abdominal Stent Graft System (Products). The Products will allow physicians to treat superficial femoral artery disease, and abdominal aortic aneurysms, respectively.
When clinicians and other healthcare personnel request the procurement of new products and services, items are vetted through the Value Analyst Committee (VAC). The VAC is a multidisciplinary group from ARMC, consisting of 21 members representing physicians, n...
Click here for full text